0.7(top 50%)
impact factor
1.2K(top 20%)
papers
16.7K(top 10%)
citations
40(top 20%)
h-index
1.2(top 50%)
extended IF
6.0K
all documents
17.2K
doc citations
55(top 20%)
g-index

Top Articles

#TitleJournalYearCitations
1High resolution BrainPET combined with simultaneous MRINuklearmedizin - NuclearMedicine2011138
2Automatic volume delineation in oncological PETNuklearmedizin - NuclearMedicine201286
3Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancerNuklearmedizin - NuclearMedicine200977
4Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancerNuklearmedizin - NuclearMedicine200772
5Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancerNuklearmedizin - NuclearMedicine200362
6Brain metastasis in lung cancerNuklearmedizin - NuclearMedicine201160
7Sentinel node mapping in the prostate cancerNuklearmedizin - NuclearMedicine201157
8Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrenceNuklearmedizin - NuclearMedicine200956
9Integration of FDG- PET/CT into external beam radiation therapy planningNuklearmedizin - NuclearMedicine201252
10Staging in childhood lymphoma: differences between FDG-PET and CTNuklearmedizin - NuclearMedicine200552
11Nuclear medicine in SARS-CoV-2 pandemia: 18F-FDG-PET/CT to visualize COVID-19Nuklearmedizin - NuclearMedicine202050
12Focal thyroid incidental uptake detected by 18F-fluorodeoxyglucose positron emission tomographyNuklearmedizin - NuclearMedicine201349
13The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131INuklearmedizin - NuclearMedicine200948
14Cryptate mediated nucleophilic 18F-fluorination without azeotropic dryingNuklearmedizin - NuclearMedicine201246
15Molecular imaging of reduced renal uptake of radiolabelled [DOTA0,Tyr3]octreotate by the combination of lysine and Gelofusine in ratsNuklearmedizin - NuclearMedicine200844
16Two or four hour [18F]FMISO-PET in HNSCCNuklearmedizin - NuclearMedicine201144
17Diagnostic performance of 18F-FDG PET/CT, ultrasonography and MRINuklearmedizin - NuclearMedicine201441
18Impact of FDG PET on the management of TBC treatmentNuklearmedizin - NuclearMedicine201041
19Integrated FDG-PET/CT for detection, therapy monitoring and follow-up of granulocytic sarcomaNuklearmedizin - NuclearMedicine200940
20Incidental uptake of 18F-fluorodeoxyglucose in the prostate glandNuklearmedizin - NuclearMedicine201439
21Combination of MRI and dynamic FET PET for initial glioma gradingNuklearmedizin - NuclearMedicine201438
22Percutaneous thermal microwave ablation of thyroid nodulesNuklearmedizin - NuclearMedicine201436
23Comparison of 18F-FDG and 67Ga-citrate in sarcoidosis imagingNuklearmedizin - NuclearMedicine200835
24Synthesis and biological evaluation of a (99m)Tc-labelled cyclic RGD peptide for imaging the alphavbeta3 expressionNuklearmedizin - NuclearMedicine200434
25MIBI scintigraphy in hypofunctioning thyroid nodulesNuklearmedizin - NuclearMedicine200933
26Risk stratification of patients with locally aggressive differentiated thyroid cancerNuklearmedizin - NuclearMedicine201033
27Prolonged back pain attributed to suspected spondylodiscitisNuklearmedizin - NuclearMedicine201232
28Can peptide receptor radionuclide therapy be safely applied in florid bone metastases?Nuklearmedizin - NuclearMedicine201431
29Variation of system performance, quality control standards and adherence to international FDG-PET/CT imaging guidelinesNuklearmedizin - NuclearMedicine201431
30Preoperative risk stratification using 18F-FDG PET/CT in women with endometrial cancerNuklearmedizin - NuclearMedicine201130
31Influence of PET reconstruction para meters on the TrueX algorithmNuklearmedizin - NuclearMedicine201330
32Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapyNuklearmedizin - NuclearMedicine201830
33Value of combined XCT/SPECT technology for avoiding false positive planar 123I-MIBG scintigraphyNuklearmedizin - NuclearMedicine200430
34124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impactNuklearmedizin - NuclearMedicine200730
35Distant metastatic lesions in patients with differentiated thyroid carcinomaNuklearmedizin - NuclearMedicine201329
36Real-time ultrasound and freehand-SPECTNuklearmedizin - NuclearMedicine201429
37Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolizationNuklearmedizin - NuclearMedicine201428
38CME-FragebogenNuklearmedizin - NuclearMedicine200827
39Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDPNuklearmedizin - NuclearMedicine201627
40Combination of ultrasound guided percutaneous microwave ablation and radioiodine therapy in benign thyroid diseasesNuklearmedizin - NuclearMedicine201526
41Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinomaNuklearmedizin - NuclearMedicine201726
42Multi-centre calibration of an adaptive thresholding method for PET-based delineation of tumour volumes in radiotherapy planning of lung cancerNuklearmedizin - NuclearMedicine201225
43Percutaneous microwave ablation of benign thyroid nodulesNuklearmedizin - NuclearMedicine201525
44FDG uptake in primary squamous cell carcinoma of the head and neckNuklearmedizin - NuclearMedicine201124
45Global scaling for semi-quantitative analysis in FP-CIT SPECTNuklearmedizin - NuclearMedicine201424
46Reference range for thyrotropinNuklearmedizin - NuclearMedicine201524
4799mTc-labeled ubiquicidin scintigraphyNuklearmedizin - NuclearMedicine201223
48MRI versus bone scintigraphyNuklearmedizin - NuclearMedicine201223
49FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic reviewNuklearmedizin - NuclearMedicine200923
5018FDG-PET to assess recurrence and long term survival in patients with malignant melanomaNuklearmedizin - NuclearMedicine201322